Umberger Traci S sold $901K of KMTS

Umberger Traci S (See Remarks) sold 30,000 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at $30.03 ($0.90M total) on 2026-10-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Umberger Traci S
Published Oct 29, 2026, 10:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 10:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$KMTS
Neutral
medium confidence
Mentioned
$KMTS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

The disclosure confirms an open-market sale of 30,000 shares at $30.0294 per share on 2026-10-27, with holdings after the transaction of 195,825 shares, under a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor insider activity for sentiment, but a 10b5-1 sale is generally not a strong standalone catalyst.

03

What to watch

The filing does not indicate whether other insiders sold/bought around the same time, nor does it provide context on total insider ownership changes beyond the post-transaction share count.

Relevance 4/10Novelty 4/10Timing: SEC Form 4 filed 2026-10-29, covering a sale dated 2026-10-27.

Background

This is an SEC Form 4 insider transaction disclosure for Kestera Medical Technologies, Ltd. (KMTS), reported by officer/director Traci S Umberger.

Company-level read

Ticker impact

$KMTSNeutralMedium confidence
Context

Insider Traci S Umberger sold 30,000 shares of KMTS for about $900,882 under a pre-arranged 10b5-1 plan filed with the SEC Form 4.

Expected impact

Likely neutral to slightly negative near-term as traders may briefly price in insider selling, though 10b5-1 structure reduces interpretability.

Evidence & confidence

The article provides only the sale details and explicitly notes a pre-arranged 10b5-1 plan, which usually dampens inference about company fundamentals.

Market effects

No clear sector read-through from a single routine insider sale.

None.

None.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, the market may overreact; price impact could be negligible once traders recognize it as pre-scheduled.

Key entities

  • KMTS

    Kestera Medical Technologies, Ltd., the company whose insider sale is disclosed.

  • Traci S Umberger

    Officer and director who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$KMTSMedAI 8/10

Kestra study shows 100% shock conversion in wearable defibrillator

Kestra Medical Technologies (KMTS) reported 100% conversion success in its ASSURE Wearable Cardioverter Defibrillator study, meeting safety and effectiveness goals. The study, involving 21,612 patients, showed a 0.0065 inappropriate-shock rate and 94% of patients with no false alarms. The company plans an algorithm update to reduce inappropriate shocks by 70%.

$KMTSHigh

Why is Kestra Medical stock gaining today?

Kestra Medical Technologies (KMTS) stock rose 0.4% to $29.50 in pre-market trading after Evercore ISI initiated coverage with an Outperform rating and $34.00 price target. The firm cited Kestra's potential in the wearable cardioverter defibrillator market, projected 30%+ annual revenue growth, and gross margin expansion to mid-70% by 2030. The move contrasts with a mixed broader market.

$KMTSHighAI 8/10

Kestra Medical Technologies Signals Profitable Growth Path

Kestra Medical Technologies (KMTS) reported Q1 revenue of $31M, up 60% YoY, with gross margin at 56.5%, up from 45.7% YoY. The company raised 2027 revenue guidance to $141M and expects profitability within a few years. Management highlighted strong growth drivers, including market expansion and automation.